)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
ImageneBio
ImageneBio (IMA) investor relations material
ImageneBio Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary9 Nov, 2026
Executive summary
Olevaprubart (IMG-007), a non-depleting anti-OX40 antibody, is in development for atopic dermatitis (AD) and alopecia areata (AA).
AD and AA trials are advancing; $126.6M in cash, cash equivalents and marketable securities is expected to fund planned operations into Q1 2028.
No Kaposi sarcoma cases have been observed across clinical trials to date.
Financial highlights
Q3 2026 license revenue was $0; operating expenses and operating loss were $17.3M vs. $26.2M YoY, and net loss was $15.6M vs. $24.8M.
Q3 net loss per share was $0.91 vs. $2.91; weighted-average shares were 17.1M vs. 8.8M YoY.
9M 2026 revenue was $0 vs. $0.8M; operating loss was $41.2M vs. $39.5M and net loss was $36.4M vs. $38.4M.
9M net loss per share was $2.45 vs. $9.98; weighted-average shares were 14.9M vs. 4.6M, reflecting the post-merger capital structure and warrant shares.
Outlook and guidance
ADAPTIVE Phase 2b topline data are expected in Q4 2027; the trial and long-term extension continue under an amended protocol.
AA Phase 2 is expected to start by year-end 2026, with initial data expected in 2028; objectives include benefit-risk characterization and dose selection.
$126.6M in cash, cash equivalents and marketable securities is expected to fund planned operations into Q1 2028; further funding will be needed for development and potential commercialization.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from ImageneBio
- Olevaprubart advances in phase IIb with robust efficacy, safety, and funding into 2028.IMA
H.C. Wainwright 28th Annual Global Investment Conference - Up to $200M in securities registered, including $17M at-the-market sales via Jefferies.IMARegistration filing
- Registering 5.77M shares for resale from a $30M private placement; no proceeds to the company.IMARegistration filing
- Net loss rose to $20.8 million as clinical pipeline advanced and cash reserves support operations into 2028.IMAQ2 2026
- Net loss narrowed to $49.2M as merger with Inmagene and IK-595 prioritization shaped 2024.IMAQ4 2024
- Net loss narrowed sharply as the company pivots to a merger-focused strategy and winds down R&D.IMAQ2 2025
- Q3 net loss was $24.8M as IMG-007 advanced in trials and cash reached $142.6M.IMAQ3 2025
- Strong cash position and advancing clinical trial for IMG-007 with robust safety data.IMAQ4 2025
- Q1 2026 net loss was $10.6M, with $117.2M in cash and IMG-007 advancing in two indications.IMAQ1 2026
Next ImageneBio earnings date
Q4 202610 Mar, 2027
ImageneBio
Next ImageneBio earnings date
Q4 202610 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)